Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20
What Are The Growth Projections For The Recombinant DNA Technology Market Size During 2025–2029?
The market encompassing recombinant DNA technology has exhibited robust expansion across recent years, with projections indicating a climb from a valuation of $858.94 billion in 2024 to $913.42 billion by 2025, reflecting a compound annual growth rate of 6.3%. This upward trajectory observed throughout the historical period primarily stems from escalating healthcare requirements, the expansion within the biopharmaceutical sector, augmented funding directed towards research and development activities, and the nascent development of individualized medical treatments.
Driven by several key factors, the recombinant DNA technology market anticipates robust expansion moving forward, projecting a valuation of $1299.96 billion by the year 2029, achieving a compound annual growth rate (CAGR) of 9.2% throughout the projection timeframe; this upward trajectory is fueled by the increasing prevalence of long-term illnesses, the emergence of new biotechnology ventures, heightened investment flowing into the biotech sector, the worldwide expansion of these markets, alongside greater public understanding and acceptance.
Unlock Your Free Sample Report for Exclusive Market Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=8233&type=smp
What Are The Drivers Pushing New Developments In The Recombinant DNA Technology Market?
The escalating incidence of long-lasting health conditions is anticipated to fuel the expansion of the recombinant DNA technology sector. These long-term ailments, characterized by their duration of at least twelve months, demand ongoing medical attention, impose limitations on routine daily functions, or involve both circumstances. Recombinant DNA techniques have markedly advanced medical treatment by enabling the production of biopharmaceutical proteins utilized in medications and by employing gene therapy to rectify diseased states via the substitution of faulty genetic material with functional segments. Demonstrating this trend, projections from the World Health Organization, a global intergovernmental body situated in Switzerland, indicated in February 2024 that the number of new cancer diagnoses globally is expected to surpass 35 million by 2050, signifying a substantial 77 percent surge from the approximately 20 million cases estimated for 2022; consequently, this rise in chronic illnesses serves as a major catalyst for the growth trajectory of the recombinant DNA technology market.
Which Key Segments Fueling The Recombinant DNA Technology Market?
The recombinant dna technologymarket covered in this report is segmented –
1) By Product Type: Recombinant Protein Drugs, Vaccines, Genetically Modified Crops, Expression Systems, Cell And Gene Therapy, Gene Editing
2) By Component Type: Expression System, Cloning Vector
3) By Application Type: Food And Agriculture, Health And Disease, Environment, Other Application Types
4) By End-Use Type: Biotechnology And Pharmaceutical Companies, Academic And Government Research Institutes, Other End-Use Types
Subsegments:
1) By Recombinant Protein Drugs: Hormones, Growth Factors
2) By Vaccines: Recombinant Viral Vaccines, Recombinant Bacterial Vaccines, Subunit Vaccines
3) By Genetically Modified Crops: Herbicide-Tolerant Crops, Insect-Resistant Crops, Nutritionally Enhanced Crop
4) By Expression Systems: Bacterial Expression Systems, Yeast Expression Systems, Mammalian Expression Systems
5) By Cell And Gene Therapy: Cell-Based Therapies, Gene Replacement Therapies, CAR T-Cell Therapies
6) By Gene Editing: CRISPR Or Cas9 Technologies, TALENs (Transcription Activator-Like Effector Nucleases), ZFNs (Zinc Finger Nucleases)
What Key Innovation Trends Are Fueling Advancements In The Recombinant DNA Technology Market?
Driving forces within the recombinant DNA technology sector are heavily influenced by ongoing technological progress, compelling key market participants to concentrate on developing novel solutions to maintain their competitive standing. A prime illustration of this innovative drive is the August 2022 introduction of ZYNTEGLO by Bluebird bio, a biotechnology entity situated in the United States; this treatment, which the U.S. Food and Drug Administration (FDA) has officially sanctioned, represents a singular gene therapy intervention designed to address the root genetic mechanism of beta-thalassemia, thereby liberating affected individuals from the necessity of perpetual red blood cell transfusions. Utilizing an ex-vivo lentiviral vector to alter the patient’s own cells, this therapy achieved the distinction of being the initial FDA-approved gene therapy for this ailment within the U.S., significantly alleviating the substantial, life-long challenges associated with beta-thalassemia management.
Which Major Industry Participants Are Leading The Recombinant DNA Technology Market Growth?
Major companies operating in the recombinant DNA technology market are Profacgen BioTech Corp., Amgen Inc., Novartis International AG, GenScript Biotech Corporation, Pfizer Inc., Novo Nordisk A/S, Eli Lilly and Company, Sanofi S.A., Merck & Co. Inc., Biogen Inc., GlaxoSmithKline PLC, New England Biolabs Inc., Bayer CropScience, Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, Regeneron Pharmaceuticals Inc., Gilead Sciences Inc., Moderna Inc., Vertex Pharmaceuticals Incorporated, CRISPR Therapeutics AG, Editas Medicine Inc., bluebird bio Inc., Illumina Inc., Qiagen N.V., Lonza Group AG, Bio-Rad Laboratories Inc., Agilent Technologies Inc., Becton Dickinson and Company, Sartorius AG, Abcam PLC, Horizon Discovery Group PLC, Integrated DNA Technologies Inc., Twist Bioscience Corporation, Synthego Corporation, Codex DNA Inc., InvivoGen, Eurofins Scientific SE, Sarepta Therapeutics Inc., Sangamo Therapeutics Inc.
Download The Full Report For Exclusive Market Findings:
https://www.thebusinessresearchcompany.com/report/recombinant-dna-technology-global-market-report
What Are The Key Regional Factors Influencing The Recombinant DNA Technology Market Growth?
North America was the largest region in the recombinant DNA technology market share in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the recombinant DNA technology market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Version Of The Recombinant DNA Technology Market Report:
https://www.thebusinessresearchcompany.com/customise?id=8233&type=smp
Browse Through More Reports Similar to the Global Recombinant DNA Technology Market 2025, By The Business Research Company
Cells Therapy Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/cells-therapy-global-market-report
Cell Culture Consumables And Equipment Global Market Report 2025
Cell Based Assays Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/cell-based-assays-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model